U.S. CDC Now Says COVID-19 Jabs Only Have 66 Percent Efficacy! Latest Japanese Study Warns That Delta Variants Will Acquire Complete Jab Resistance!
Source: Delta Variant And COVID-19 Shots Aug 26, 2021 3 years, 2 months, 2 weeks, 5 days, 1 hour, 31 minutes ago
For the past three months, the world was bombarded with numerous studies claiming that the various COVID-19 jabs were still maintaining full efficacy or in some cases only a slight drop of efficacy against Delta variant. Off course most of these were studies were funded by the COVID-19 jab manufacturers either directly or indirectly and were conducted by researchers who would not hesitate to sell their mothers for the right price!
In a sudden turn of events, the U.S. CDC has now published an early release report on a study that shows that the COVID-19 jabs are only about 66% effective against the Delta variant. https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e4.htm?s_cid=mm7034e4_w
But note that the study only covered the Pfizer, Moderna and Johnson & Johnson COVID-19 jabs. It did not cover the garbage Pommy jabs that have a high rate of adverse reactions including blood clots and neither did it cover what many are terming the “pig’s urine jabs.” (What efficacy if any from the latter is really interesting but off course those receiving a red 'Ang Pao' would gladly testify to its so called miraculous properties!)
Also note that that this is an early report of the study and that it would not be surprising if the actual figure actually drops even lower over time as the study concludes.
However the decline points to the highly contagious nature of the Delta variant and underscores the importance of COVID-19 jabs to prevent severe disease, hospitalization and death, the study authors wrote.
Dr Ashley Fowlkes, the lead author and an epidemiologist for the CDC's COVID-19 Emergency Response, told media, "While we did see a reduction in the protection of the COVID-19 jab against the Delta variant, it's still two-thirds reduction of risk."
This surprising latest update is part of an ongoing study that follows health care workers, first responders and essential workers who undergo weekly testing in eight locations across six states. The weekly testing helps researchers to better track the rates of people who develop mild or no symptoms and may be less likely to get tested overall.
Of the study’s 4,217 participations, 3,483 or 83% received the COVID-19 jabs. About 65% received Pfizer, 33% received the Moderna doses and 2% received the Johnson & Johnson shot.
Interestingly between December 2020 and April 2021, the jabs were claimed to be more than 90% effective in preventing symptomatic and asymptomatic infections.
The Delta variant became more dominant Between April and August, and the efficacy began to drop, though there were still few infections. Researchers found 19 infections among 488 who did not receive the jabs and about 95% were symptomatic. They also found 24 infections among 2,352 people who received the full jabs, and 75% were symptomatic. The study didn't include details about the type or severity of symptoms.
Dr Fowlkes added, "It's still a very powerful jab. But we are also looking
towards continuing to use masks for a little bit longer."
The research team is planning future analyses that compare the different COVID-19 jabs and the types of symptoms that people who received and did not receive the jabs experienced.
Yesterday, Johnson & Johnson reported that a second dose of its jab raises antibody levels against the coronavirus. When participants received a booster shot at six months, their spike-binding antibodies increased about nine times higher than after the first dose, the company wrote in a statement.
https://www.jnj.com/johnson-johnson-announces-data-to-support-boosting-its-single-shot-covid-19-vaccine
The researchers from Johnson & Johnson also found that the booster shot increased the supply of immune cells in the body, which can attack the cells infected with the coronavirus. Those results are still being prepared for publication.
While research continues, COVID-19 jab manufacturers are still determining how long the increased antibody levels last after a booster shot.
Many latest data are revealing that the protective effects of the jabs wanes after a few months ie some claiming 4 to 5 months only while others saying 6 to 8 months.
https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e1.htm?s_cid=mm7034e1_w
Japanese Researchers Warn That The SARS-CoV-2 Delta Variant Will Eventually Acquire Complete Resistance To Wild-Type Spike COVID-19 Jabs
Japanese researchers from Osaka University based on findings from a recently conducted study are warning that The SARS-CoV-2 Delta Variant Will eventually acquire complete resistance to wild-type spike COVID-19 Jabs.
The study findings were published on a preprint server and are currently being peer reviewed.
https://www.biorxiv.org/content/10.1101/2021.08.22.457114v1
According to the study abstract, while mRNA-based vaccines provide effective protection against most common SARS-CoV-2 variants, identifying likely breakthrough variants is critical for future jab development.
The study team found that the Delta variant completely escaped from anti-N-terminal domain (NTD) neutralizing antibodies, while increasing responsiveness to anti-NTD infectivity-enhancing antibodies.
Even though the Pfizer-BioNTech BNT162b2-immune sera neutralized the Delta variant, when four common mutations were introduced into the receptor binding domain (RBD) of the Delta variant (Delta 4+), some BNT162b2-immune sera lost neutralizing activity and enhanced the infectivity.
The study team warned that unique mutations in the Delta NTD were involved in the enhanced infectivity by the BNT162b2-immune sera. Sera of mice immunized by Delta spike, but not wild-type spike, consistently neutralized the Delta 4+ variant without enhancing infectivity.
It should be stressed that considering the fact that more than 27 subspecies of the Delta variant have emerged to date with a few having three similar RBD mutations according to the GISAID database, it is necessary to develop COVID-19 jabs that protect against such complete breakthrough variants.
Thailand Medical News also further warns that already a few studies are already emerging warning about the growing prevalence of ADE caused by emerging second generation or sub-species of the Delta Variant and this is something that should be importantly focused on by the COVId-19 jab manufacturers as it is expected that the newer emerging third or fourth generation Delta variants will even cause more catastrophic ADE conditions and we will really see a frightening scenario in coming months.
https://www.thailandmedical.news/news/breaking-french-study-published-in-journal-of-infections-claims-that-ade-or-antibody-dependent-enhancement-is-occurring-in-delta-variant-infections
https://www.thailandmedical.news/news/warning-the-delta-variant-is-mutating-rapidly,-sri-lanka-reports-4-new-delta-variants,-japanese-study-warns-about-vaccine-efficacy-and-ade-issues
For more on
COVID-19 Shots, keep on logging to Thailand Medical News.
Read Also:
https://www.thailandmedical.news/news/great-news-u-s-cdc-director-rochelle-walensky-says-those-that-got-covid-19-jabs-could-suffer-more-disease-severity-and-mortality-due-to-ade
https://www.thailandmedical.news/news/breaking-four-delta-second-generation-variants-found-in-thailand-ie-ay-4,-ay-6,-ay-10-and-ay-12-more-than-27-delta-sub-variants-identified-globally
